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ABSTRACT 
On the basis that aluminium-based antiperspirant salts are designed to block apocrine 
sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the 
adjacent region of the body, it has been proposed that breast cysts may arise from 
antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term 
usage. This review collates evidence that aluminium can be absorbed from dermal 
application of antiperspirant salts and describes studies measuring levels of aluminium 
in breast tissues, including in breast cyst fluids. It is notable that breast cysts, as for 
breast cancers, start most frequently in the upper outer quadrant of the breast, which 
is the region closest to the site of underarm antiperspirant application. Mechanistic 
evidence is reviewed for a link between aluminium levels in breast tissue, cyst 
formation and development of breast cancer. If excessive use of antiperspirant is a 
cause of breast cysts, then reduction or cessation of use could provide a preventative 
or even treatment strategy. Furthermore, if cyst formation from antiperspirant use is 
an indicator of increased risk for breast cancer, then reduction in use of antiperspirant 
could also provide a strategy for reducing breast cancer risk. 
INTRODUCTION 
Cystic disease of the breast is a common benign disorder of breast biology which 
results from blockage of breast ducts and is classified according to the size of the 
cysts formed [1]. If the cysts are small and typically visible only by microscopy, the 
condition is termed “microscopic cystic disease”. Due to the small size of such cysts, 
diagnosis is usually only made when there is another lesion present and therefore the 
frequency and significance of microscopic cysts remain largely unknown. When the 
cysts are palpable and over 3mm in diameter, the condition is termed Gross Cystic 
Breast Disease (GCBD). The larger size of the cysts enables them to be clinically 
diagnosed and GCBD has been reported to occur in up to 7% of women living in 
western countries [1]. This makes GCBD the most commonly diagnosed benign breast 
disorder [1,2]. Although not life-threatening in itself, development of cysts causes 
anxiety, and treatment is invasive. GCBD arises from dilation and/or obstruction of 
ductal terminal lobular units (Figure1) which, due to retention of fluid, then swell up to 
form fluid-filled sacs [1,2]. Although gross cysts are known to be associated with 
retention of fluid and secretory material linked to the metabolic activity of the lining 
epithelial cells [1,2], the molecular basis of cyst formation and the reasons why cysts 
arise so frequently in western women remain to be identified. Aluminium-based salts 
are used as the active antiperspirant agent in underarm cosmetics to reduce sweating 
in the underarm area [3]. The main salts used are aluminium chloride, aluminium 
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chlorohydrate and aluminium zirconium chlorohydrate glycine 
complexes [3]. Their mechanism of action is thought to involve 
the formation of a physical plug at the top of the sweat ducts 
which is composed of a mixture of damaged cells and 
precipitated aluminium salts [3]. This plug then prevents the 
escape of sweat onto the skin surface which would otherwise 
generate odour from bacterial action on the sweat as it lingers 
on the skin. On the basis that antiperspirant formulations are 
designed to block apocrine sweat ducts of the axilla, and that 
breast cysts result from blocked breast ducts in the adjacent 
region of the body (Figure1), it has been hypothesised that 
breast cysts may arise from antiperspirant use if sufficient 
aluminium is absorbed into breast tissues [4-6]. Since 
antiperspirant salts are applied frequently to the underarm 
region and left on the skin, this allows for a continuous dermal 
exposure which could result in absorption of aluminium and 
deposition into underlying breast tissues. This might then give 
rise to subsequent blockage of breast ducts if sufficient 
aluminium were absorbed or accumulated over long term 
usage. Aluminium complexes have been previously linked to the 
development of granulomas at the site of antiperspirant 
application [7,8] and the use of aluminium-based vaccines is 
also known to cause itching nodules locally at the site of 




























Figure 1: Structural features of the human breast showing the sites of breast cyst formation. The 
human breast is composed of a series of ducts and lobules which are lined with epithelial cells and 
are embedded in fatty stromal tissue. It is the lining epithelial cells which produce the milk which 
then flows down the ducts to the nipple. Breast cysts result from blocked ducts in the ductal 
terminal lobular units indicated in pink. Aluminium-based antiperspirant salts are used to block 
sweat ducts in the underarm region (indicated in blue): if sufficient aluminium were absorbed over 
time, could the breast ducts not also become blocked by the same mechanism? 
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DERMAL ABSORPTION OF ALUMINIUM FOLLOWING 
UNDERARM APPLICATION OF ANTIPERSPIRANT 
In 2001, a report was published by Flarend and colleagues 
which demonstrated the principle that aluminium could be taken 
up through the skin following application of antiperspirant to 
the human underarm [11]. In this study, an antiperspirant 
formulation was applied which included the 26Al isotope and 
thus allowed aluminium to be traced from application to the 
human underarm into blood and urine [11]. Conclusions from 
this research were that aluminium uptake from a single 
application was small [11], but long-term effects of low-dose 
uptake have yet to be studied. This is pertinent to breast tissue 
in particular because this is the site adjacent to antiperspirant 
application and also because breast tissue contains high levels 
of calcium phosphate which would generate a favourable 
chemical environment for aluminium deposition. In 2004, this 
was followed by a clinical case report documenting 
physiological consequences following absorption of aluminium 
from use of underarm antiperspirant [12]. Uptake of aluminium 
in a human subject was measured as rising to 4M in the blood 
following the underarm antiperspirant use, and this was 
associated with clinical symptoms of bone pain and fatigue 
[12]. The report documents clearly that the high plasma 
aluminium levels and associated symptoms resulted from 
antiperspirant use because when antiperspirant use was 
stopped, the aluminium levels fell back to the normal range 
(0.1-0.3M) and symptoms ceased [12].  
THE EFFECT OF SHAVING ON TRANSDERMAL UPTAKE OF 
ALUMINIUM 
Current cultural practices have led to aluminium-based 
antiperspirant salts being applied to the underarm region often 
after shaving. Shaving is a procedure which can create 
abrasions in the skin, loss of stratum corneum and damage from 
hair removal [13]. This procedure could therefore be expected 
to result in increased transdermal uptake of aluminium, and in 
vitro studies provide supporting evidence for this. Using a Franz 
diffusion cell and a stripping procedure as a model for 
shaving, aluminium has been shown to be absorbed to a 
greater extent through stripped than intact skin [14]. 
Absorption of aluminium from a stick formulation containing 
aluminium chlorohydrate showed aluminium absorption of 
1.81g/cm2 for intact skin but this was increased to 
11.5g/cm2 for stripped skin [14]. The Cosmetics Directive of 
the European Union [15] recommends that these aluminium salts 
should not be applied “to irritated or broken skin” which 
conflicts with these current practices of shaving prior to 
antiperspirant application and therefore ignores the regulatory 
advice [15]. Furthermore, recent calculations by the BfR in 
Germany estimate that antiperspirant use, in conjunction with 
prior shaving, may result in absorption of aluminium at levels 
exceeding tolerable weekly intake guidance, and accordingly 
women have been advised in their report not to shave prior to 
antiperspirant use [16]. 
MEASUREMENT OF ALUMINIUM IN BREAST CYST FLUID 
Aluminium plays no known functional role in biological systems, 
but due to the activities of man [17], increasing levels of this 
non-essential metal are being found in biological tissues [18]. 
The source of the aluminium cannot be specifically identified in 
such measurements because the human population is now 
exposed through diet, vaccines and antacids as well as through 
antiperspirant use [6]. However, research has identified 
aluminium as now present in several human breast tissue 
structures (Figure 2) [6], and measurements have reported that 
aluminium is widely present in breast tissue at levels varying 
from 4 to 437 nmol/g dry weight [19]. If breast cysts result 
from blockage of breast ducts through an aluminium-mediated 
mechanism, aluminium should also be measurable in breast cyst 
fluids, and indeed, measurement has shown that aluminium is 
widely present in breast cyst fluids, at levels varying from 11 
to 330 g/L [20] (Figure 2). Classification of gross cysts into 
two types based on histology and on ion/protein/hormone 
concentrations in the cyst fluid has enabled aluminium levels to 
be measured separately in type 1 and type 2 cyst fluids. 
Median levels of aluminium have been found to be higher in 
type 1 (150g/L) (range 80-330 g/L) than in type 2 
(32g/L) (range 11-39 g/L) breast cyst fluids, and both were 
higher than in blood serum (6g/L) (range 3-9g/L) [20]. The 
reasons for and consequences of the different levels of 
aluminium in the type 1 and type 2 cyst fluids remains to be 
determined, but they might explain the different Na+ / K+ion 
concentrations reported in the two cyst types [2,21]. Type 1cyst 
fluids have low Na+ / high K+ ion concentrations (Na+/K+<3), 
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whilst, by contrast, type 2 cyst fluids contain high Na+ / low K+ 
ion concentrations (Na+/K+>3) [2,21]. Since the electrolyte 
composition of the breast cyst fluid will depend on the Na+/K+-
ATPase activity of the lining epithelial cells, and since chronic 
exposure to aluminium has been shown to alter cellular 
Na+/K+-ATPase activity [22,23], differences in ion 
concentrations between the two main cyst types might be 



















DISPROPORTIONATE INCIDENCE OF CYSTS IN THE UPPER 
OUTER QUADRANT OF THE BREAST 
It is notable that breast cysts occur more frequently in the 
upper outer quadrant compared with other regions of the 
breast [1]. An explanation of this disproportionate incidence is 
lacking other than there being more target ductal tissue in that 
region [1]. However, coincidentally this is the location adjacent 
to the site of application of antiperspirant to the underarm. If 
this were an explanation, then it might be expected that 
aluminium levels would be higher in that region of the breast. 
Indeed, measurements of aluminium concentrations at four 
serial locations across the breast showed that the aluminium 
content of defatted tissue was significantly higher in the outer 
than the inner breast regions [19]. A similar disproportionate 
incidence also occurs for breast cancers in the upper outer 
quadrant of the breast [24,25]. Whilst national statistics are 
not collated for breast cysts, national statistics offices for 
England, Wales and Scotland have collected information 
concerning the site of incidence of cancer in the breast since 
1979, and these data show that over half of breast cancers 
start in the upper outer quadrant (Figure 3) [24,25]. 
Furthermore, a rising incidence in that specific region over 
recent decades [24,25] cannot be explained solely by more 
epithelial tissue in that region, and the hypothesis of a link 
between increasing use of underarm antiperspirant and breast 






Figure 2: Human breast tissue structures in which aluminium has been measured as 
present: references are indicated in parentheses. 
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IS THERE A LINK BETWEEN BREAST CYSTS AND SUBSEQUENT 
DEVELOPMENT OF BREAST CANCER? 
Over the years, several studies have suggested that the 
presence of gross cysts may be linked with a higher subsequent 
risk of breast cancer development [1,2,21,26-28]. Notably, the 
highest incidence of cysts is in women of the 35-50 age group 
with a sharp decline after menopause [1,2] whilst 80% of 
breast cancers occur later in life in the over 50 age group [29], 
which provides a compatible timeline for such a link. Many 
epidemiological studies have concluded that there is an 
increased frequency of subsequent breast cancer in women 
who have had GCBD but not all [2]. This indicates that GCBD is 
not a precancerous lesion in itself, but is suggestive of an 
associated increased risk [30]. Since some studies have 
suggested that those with type 1 cysts may be at greater risk 
[2,21,26-28,30], and it was the type 1 breast cyst fluids which 
contained the higher levels of aluminium [20], further research 
is justified to test whether tissue levels of aluminium might 
provide a prognostic indicator. It might be that levels of 
aluminium high enough in the breast tissue to block a breast 
duct and cause formation of a cyst would be indicative of rising 
levels of aluminium in the breast tissue in general, which if not 
checked or reversed, could eventually lead to development of 
cancer. 
IS THERE A LINK BETWEEN ALUMINIUM-BASED 
ANTIPERSPIRANT SALTS AND DEVELOPMENT OF BREAST 
CANCER? 
Many studies have now been published suggesting a potential 
link between exposure of the human breast to aluminium and 
development of breast cancer. In terms of exposure scenarios, 
some tissue measurements report higher levels of aluminium in 
breast tissue of women with breast cancer. Using nipple 
aspirate fluid, which is secreted by ductal and lobular 
epithelial cells of the breast and therefore reflects the breast 
microenvironment, aluminium, was measured at higher levels in 
samples from breast cancer patients than from women who did 
not have cancer at the time of sampling [31]. The mean level of 
aluminium in the nipple aspirate fluids from women with breast 
cancer was 268.4+/-28.1 g/L but in unaffected women was 
131.3+/-9.6 g/L [31]. Using breast tissue, other studies have 
also reported higher levels of aluminium in malignant breast 
tissue than in adjacent unaffected tissue [32-35]. Only few 
epidemiological studies have attempted to address any link 
between antiperspirant use and breast cancer. An early 
epidemiological study reported that within a population of 
breast cancer patients, those who used more antiperspirant 
were diagnosed at a younger age with breast cancer [36]. 
However, two other epidemiological studies failed to find any 
 
Figure 3: More than half of breast cancers originate in the 
upper outer quadrant of the breast. In the UK, incidence is 
recorded annually in the seven regions of the breast shown 
here and the percentage proportion of total incidence in 
each region is shown as published for the year of 2006 [25]. 
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association between antiperspirant use and breast cancer 
[37,38]. These early studies were impeded by the difficulty in 
finding control populations of women who had never been 
exposed to antiperspirant or who even understood the 
difference between antiperspirant and deodorant. A more 
recent epidemiological study from Austria used actual tissue 
measurements of aluminium as a quantitative indication of 
exposure, and reported associations both between 
antiperspirant use and aluminium levels in breast tissue and 
between aluminium tissue levels and development of breast 
cancer at young age [39]. Recent animal model studies back 
up the concept that exposure of non-transformed breast 
epithelial cells to aluminium salts can cause alterations to the 
cells which result in transformation and subsequent growth of 
the cells into tumours in mice [40]. In vitro studies have shown 
that exposure to aluminium can enable development of several 
of the hallmarks of cancer [41,42] in breast epithelial cells 
including genomic instability, inappropriate proliferation and 
increased migration/invasion [6]. In addition, aluminium is a 
metalloestrogen [43] and exposure to excessive oestrogen is a 
risk factor for breast cancer [44]. With regard to DNA 
damage, aluminium has been shown to result in DNA damage 
in a micronucleus assay [45] and in Comet assays [46,47] in 
vitro, and in vivo using a zebra fish model [48], which support 
the potential for aluminium to generate genomic instability in 
cells and tissues. Aluminium chloride has been shown to induce 
DNA double strand breaks in non-transformed MCF10A human 
mammary epithelial cells [49], and in these same cells, to 
induce anchorage-independent growth in a soft agar assay 
[49] which is considered predictive of tumour growth in an 
animal [50]. Furthermore, exposure of MCF10A cells to 
aluminium chloride or aluminium chlorohydrate has been shown 
to cause down regulation of both mRNA and protein for BRCA1 
[51], which is a gene critical for DNA repair in breast cells, so 
much so that inherited defects are known to be associated with 
increased breast cancer risk [52,53]. With regard to migration 
and invasion, in vitro models have revealed that long-term 
exposure (>20 weeks) to aluminium salts can increase 
migratory and invasive properties of human breast cancer cells 
in culture [54,55]. Such alterations are characteristic of the 
metastatic process [56] and are especially pertinent to breast 
cancer where the major cause of mortality is from tumour 
growth at metastatic sites rather than at the primary site in the 
breast [44].  
DISCUSSION AND CONCLUSIONS 
Published evidence is broadly supportive of proposed links 
between the presence in breast tissue of excessive aluminium 
from antiperspirant use and both breast cyst formation and 
breast cancer development. Further evidence over a longer 
time frame has suggested an association between GCBD and 
subsequent development of breast cancer. It would seem likely 
that mechanisms would be different, with aluminium acting in 
breast cyst formation through a physical mechanism involving 
obstruction of ducts, but in breast cancer through intracellular 
molecular alterations leading to development of hallmarks of 
cancer in target epithelial cell(s). Such a basic difference in 
mechanisms would be consistent with the lack of any direct links 
but rather with more nebulous associated risks. Aluminium has a 
long-established toxicological profile of cellular actions, and it 
could be that the excessive build-up of aluminium leading to 
duct obstruction is indicative of rising tissue aluminium levels 
which could lead to subsequent cancer formation if left 
unchecked. However, the stochastic and multi-step requirements 
for cancer development would also be consistent with the lack 
of any direct link. In particular, the strong link between 
excessive oestrogen exposure and breast cancer development 
[44] would be a complicating interacting factor. However, with 
such a high proportion of both cysts and cancers starting in the 
same region of the breast (upper outer quadrant), and if 
aluminium build-up in the tissues is mechanistically involved, 
then it becomes questionable as to whether the diagnosis of a 
cyst should be a relief or rather a warning sign of aluminium 
build-up in the region of the breast most prone to cancer 
incidence, and this needs further research. If excessive use of 
antiperspirant is a cause of breast cysts, then reduction or 
cessation of use could provide a non-invasive preventative or 
even treatment strategy. Furthermore, if excessive cyst 
formation is an indicator of increased risk for breast cancer, 
then reduction in use of antiperspirant could also provide a 
strategy for reducing breast cancer risk. Anecdotally, several 
women from the general public have told me of their 
experiences of breast cysts which disappeared following 
cessation of antiperspirant use. These observations need to be 
followed up by controlled clinical studies. However, if breast 
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cysts could be reversed simply by ceasing use of 
antiperspirant, then this could reduce the health service burden 
of this common benign breast condition. Furthermore, the 
implied anecdotal reversibility could be exploited to 
investigate cause and effect. Several studies have now 
reported gynecomastia (excessive breast growth) in men 
following dermal exposure to cosmetic products containing 
oestrogenic compounds and these products have been 
identified as causative because symptoms reversed upon 
cessation of exposure [57,58]. Such studies where reversibility 
of symptoms can be linked to cessation in use of a specific 
product are becoming important approaches to identifying 
effects of endocrine disrupting agents [59]. Since cancer is not 
a reversible condition, such studies need to be performed in 
conditions linked to cancer, and the association between GCBD 
and breast cancer provides one possible opportunity. For this 
reason, studies should now be performed to test the hypothesis 
that cessation in use of aluminium-based antiperspirant salts 
could prevent or reverse breast cyst formation. 
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